Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Poloxamer 181 is a synthetic, nonionic surfactant belonging to the poloxamer family, composed of a central hydrophobic polyoxypropylene chain flanked by two hydrophilic polyoxyethylene chains. It is commonly sold under the trade names Pluronic L-61 and Synperonic L61, and is used primarily as a solubilizing agent, emulsifier, and excipient in industrial, cosmetic, and pharmaceutical applications. Its key technological properties include temperature- and concentration-dependent micelle and gel formation, which can be useful for drug delivery purposes. While poloxamers including 181 have been evaluated for enhancing drug delivery and sensitizing drug-resistant cancers, they are not themselves therapeutic molecular targets, receptors, or enzymes.
Functions by forming micelles that encapsulate hydrophobic drugs, thereby increasing their solubility, bioavailability, and delivery. Can sensitize resistant cancer cells, likely by modifying cellular uptake through membrane effects.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poloxamer 181.